April 1, 2025 — Irvine, CA – TAE Life Sciences (TLS), a leader in next-generation Boron Neutron Capture Therapy (BNCT) solutions, has announced a distribution agreement with alphaXRT, a premier provider of advanced radiation therapy technologies. Under this partnership, alphaXRT will distribute TAE Life Sciences’ Alphabeam™ BNCT system and novel boron drugs, while also providing associated services across Australia and New Zealand.
As part of the agreement, alphaXRT will hold the regulatory certificate for BNCT in the region, ensuring compliance with local medical and regulatory standards. This collaboration will expand access to BNCT, offering patients with difficult-to-treat cancers an innovative and targeted radiation therapy option.
“This agreement with alphaXRT marks a significant step forward in making BNCT more accessible to patients in Australia and New Zealand,” said Rob Hill, CEO of TAE Life Sciences. “With alphaXRT’s deep expertise in radiation oncology and regulatory affairs, we are confident that this partnership will drive adoption and establish BNCT as a key treatment modality in the region.”
The Alphabeam BNCT system is a cutting-edge accelerator-based neutron source designed to deliver safe, effective, and precisely targeted radiation therapy. By leveraging boron-10 drugs, BNCT enables selective tumor destruction while preserving surrounding healthy tissue—making it a promising option for patients with recurrent or treatment-resistant cancers.
“TAE Life Sciences is at the forefront of BNCT innovation, and we are thrilled to be their distributor in Australia and New Zealand,” said Richard Neale, Managing Director of alphaXRT. “We look forward to working closely with hospitals and cancer treatment centers to bring this transformative therapy to more patients.”
This partnership further underscores TAE Life Sciences’ commitment to expanding global access to BNCT and advancing the future of radiation oncology.
About TAE Life Sciences
TAE Life Sciences is a biotechnology company pioneering the development of accelerator-based BNCT solutions for treating aggressive and treatment-resistant cancers. The company’s Alphabeam BNCT system and novel boron drugs are designed to enable safe and effective BNCT treatment worldwide. More information about TAE Life Sciences is available at taelifesciences.com.
About alphaXRT
alphaXRT was founded in 1990 by Richard Neale, who identified an opportunity to introduce cutting-edge radiation oncology technologies into Australasia, giving clinicians access to the world’s most innovative, precise, personalized treatments to give every patient a future with options. Today alphaXRT is the leading independent supplier of equipment to all radiation oncology departments in Australia and New Zealand. Learn more at alphaxrt.com.
